ESGO integrated molecular risk | Total number of women | Open surgery | Laparoscopic | SLN | LND | Unilateral SNB and contralateral LND | No LN treatment |
---|---|---|---|---|---|---|---|
Low risk | 22 (56.4%) | 2 (5.1%) | 20 (51.3%) | 18 (46.2%) | 0 | 0 | 4 (10.3%) |
Intermediate | 4 (10.3%) | 0 | 4 (10.3%) | 3 (7.7%) | 1 (2.6%) | 0 | 0 |
HIR | 3 (7.7%) | 1 (2.6%) | 2 (5.1%) | 0 | 2 (5.1%) | 1 (2.6%) | 0 |
High | 9 (23.1%) | 5 (12.8%) | 4 (10.3%) | 2 (5.1%) | 5 (12.8%) | 2 (5.1%) | 1 (2.6%) |
Advanced | 1 (2.6%) | 1 (2.6%) | 0 | 0 | 0 | 0 | 1 (2.6%) |
Number of patients (%) | ||
---|---|---|
Low risk | 21 (53.8%) | |
Intermediate risk | 5 (12.8%) | |
High-intermediate risk | 2 (5.1%) | |
High risk | 10 (25.6%) | |
Advanced metastatic | 1 (2.6%) | |
Low risk | 22 (56.4%) | |
Intermediate risk | 4 (10.3%) | |
High-intermediate risk | 3 (7.7%) | |
High risk | 9 (23.1%) | |
Advanced metastatic | 1 (2.6%) |
Age at time of diagnosis | Multiple-classifier EC | POLE variant | Tumor type | FIGO stage | Lymphovascular invasion | Clinical risk assessment | |
---|---|---|---|---|---|---|---|
76 | POLEmut and p53abn | P286R | endometrioid | IIIC2 | Yes | High | |
75 | POLEmut and p53abn | P286R | carcinosarcoma | IB | Yes | High | |
70 | MMRd and p53abn | wild-type | endometrioid | IA | No | Low | |
87 | MMRd and p53abn | wild-type | endometrioid | IIIB | Yes | High | |
53 | POLEmut and p53abn | P286R | endometrioid | IA | No | Low | |
52 | POLEmut and p53abn | P286R | endometrioid | IA | No | Intermediate |
65.2 years (min 32 – max 86) | ||
31 (17–43) | ||
Parity (median, range) | 2 (0–5) | |
Spontaneuos abortion (median, range) | 0 (0–2) | |
Pre-menopausal | 5 (12.8%) | |
Post-menopausal | 34 (87.2%) | |
CA125 (n = 32) | 136.3 (min 2 – max 2084) | |
CEA (n = 32) | 3.4 (min 2 – max 17) | |
IA | 21 (54%) | |
IB | 8 (20.5%) | |
II | 1 (2.6%) | |
IIIA | 2 (5.1%) | |
IIIB | 2 (5.1%) | |
IIIC1 | 3 (7.7%) | |
IIIC2 | 1 (2.6%) | |
IV | 1 (2.6%) | |
Type 1 | 36 (92.3%) | |
Type 2 | 3 (7.7 %) | |
POLEmut | 1 (2.6%) | |
MMRd | 13 (33.3%) | |
NSMP | 22 (56.4%) | |
p53abn | 3 (7.7%) |